Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on Pacific Biosciences (NASDAQ:PACB) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
2
6
0
0
Last 30D
1
0
0
0
0
1M Ago
0
0
3
0
0
2M Ago
2
2
3
0
0
3M Ago
0
0
0
0
0
Analysts have set 12-month price targets for Pacific Biosciences, revealing an average target of $3.64, a high estimate of $8.00, and a low estimate of $2.00. A decline of 57.92% from the prior average price target is evident in the current average.
Diving into Analyst Ratings: An In-Depth Exploration
The analysis of recent analyst actions sheds light on the perception of Pacific Biosciences by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst
Analyst Firm
Action Taken
Rating
Current Price Target
Prior Price Target
Tycho Peterson
Jefferies
Announces
Buy
$4.00
-
Tejas Savant
Morgan Stanley
Lowers
Equal-Weight
$4.00
$10.00
David Westenberg
Piper Sandler
Lowers
Neutral
$2.00
$6.50
Luke Sergott
Barclays
Lowers
Equal-Weight
$2.00
$3.00
Matthew Sykes
Goldman Sachs
Lowers
Neutral
$2.50
$7.00
Eve Burstein
Bernstein
Lowers
Outperform
$2.50
$9.00
Matthew Sykes
Goldman Sachs
Lowers
Neutral
$2.50
$7.00
Sung Ji Nam
Scotiabank
Lowers
Sector Outperform
$8.00
$15.00
Daniel Brennan
TD Cowen
Lowers
Buy
$2.50
$12.00
Luke Sergott
Barclays
Lowers
Equal-Weight
$3.00
$8.00
Matthew Sykes
Goldman Sachs
Lowers
Buy
$7.00
$9.00
Key Insights:
Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Pacific Biosciences. This ...Full story available on Benzinga.com
Benzinga